The Persistent Challenge of Long COVID and the Search for Therapies
Since the onset of the SARS-CoV-2 pandemic, the medical community has grappled with the long-term sequelae of the infection, commonly referred to as Long COVID or Post-Acute Sequelae of SARS-CoV-2 (PASC). Characterized by a diverse array of symptoms including fatigue, dyspnea, cognitive impairment, and functional limitations, Long COVID represents a significant public health burden. While the exact pathophysiology remains elusive, persistent systemic inflammation has emerged as a leading hypothesis. This has led researchers to investigate whether established anti-inflammatory agents could mitigate symptoms and improve quality of life for these patients.
Among the candidates, colchicine—a potent anti-inflammatory drug traditionally used for gout and pericarditis—has garnered significant interest. Colchicine inhibits microtubule polymerization and disrupts the NLRP3 inflammasome, a key component of the innate immune response that has been implicated in the cytokine storm of acute COVID-19. However, its efficacy in the chronic phase of the disease remained unproven until the recent publication of a rigorous randomized clinical trial in JAMA Internal Medicine.
The Mechanistic Rationale: Why Colchicine?
Colchicine’s mechanism of action is multifaceted. By binding to tubulin, it inhibits leucocyte chemotaxis, adhesion, and phagocytosis. More importantly, in the context of COVID-19, it prevents the activation of the NLRP3 inflammasome, which reduces the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18.
During the acute phase of SARS-CoV-2 infection, several trials, such as the COLCORONA trial, suggested potential benefits in reducing hospitalizations among non-hospitalized patients, although results across various studies were mixed. The hypothesis for the current trial was that by suppressing persistent low-grade inflammation in the post-acute phase, colchicine could alleviate the metabolic and physiological disruptions that lead to functional decline in Long COVID patients.
Study Design: A Multi-Center Approach to Functional Recovery
This double-blind, 1:1 randomized clinical trial was conducted across eight hospitals in six states in India between January 2022 and July 2023. The study, led by Bassi and colleagues, aimed to determine if colchicine was superior to placebo in improving functional outcomes over a 52-week period.
Participant Selection and Inclusion Criteria
The researchers recruited 346 participants with confirmed SARS-CoV-2 infection who continued to experience symptoms for at least four weeks post-infection. To ensure the study population had a high probability of inflammatory-driven symptoms, inclusion required participants to meet at least one of two criteria: functional limitation (defined as a Post-COVID-19 Functional Status [PCFS] scale grade of 2 or more) and/or elevated inflammatory markers (high-sensitivity C-reactive protein [hs-CRP] > 0.20 mg/dL or a neutrophil-to-lymphocyte ratio [NLR] > 5).
Intervention and Monitoring
Participants were randomized to receive either colchicine (0.5 mg once or twice daily, adjusted for body weight) or a matching placebo for 26 weeks. The primary endpoint was the change in the distance walked during a 6-minute walk test (6MWT) from baseline to 52 weeks. Secondary outcomes were comprehensive, including changes in hs-CRP, NLR, and various patient-reported outcome measures (PROMs) such as the EQ-5D-5L for quality of life, the Hospital Anxiety and Depression Scale (HADS), and the FACIT-Fatigue scale.
Key Findings: Analyzing the Evidence
The results of the trial were largely definitive, showing a lack of therapeutic efficacy for colchicine across nearly all measured parameters.
Primary Outcome: The 6-Minute Walk Test
At the 52-week mark, both groups showed modest improvements in their walking distance, likely reflecting the natural history of recovery over time. However, there was no statistically significant difference between the intervention and control groups. The colchicine group saw a mean increase of 35.5 meters, while the placebo group saw an increase of 29.96 meters. The mean difference of 5.59 meters (95% CI, -9.00 to 20.18; P = .45) failed to reach statistical significance and was well below the threshold for clinical relevance.
Secondary Outcomes and Inflammatory Markers
Perhaps most surprising was the impact—or lack thereof—on inflammatory markers. Despite colchicine’s known pharmacological profile, there were no significant differences in the reduction of hs-CRP or NLR between the two groups. This suggests that either the dose was insufficient to dampen the specific inflammatory pathways active in Long COVID, or that these markers do not adequately capture the localized or tissue-specific inflammation that may drive the syndrome.
Furthermore, patient-reported outcomes for fatigue, dyspnea, anxiety, and depression showed no divergence between the colchicine and placebo arms. Quality of life scores improved similarly in both groups, reinforcing the idea that the observed recovery was independent of the pharmacological intervention.
The Respiratory Anomaly
The study did note a small, statistically significant difference in the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC). The colchicine group showed a slightly better preservation of this ratio compared to placebo. However, the authors were quick to note that this difference (mean difference of 0.04) was not clinically meaningful and likely represented a chance finding given the number of secondary outcomes tested.
Expert Commentary and Clinical Interpretation
The failure of colchicine to show benefit in this trial is a significant blow to the “persistent systemic inflammation” hypothesis as a singular driver for Long COVID that can be addressed by broad anti-inflammatory therapy.
Several factors may explain these results. First, Long COVID is increasingly recognized as a heterogeneous condition. Some patients may suffer from viral persistence, others from autoimmunity, and others from microvascular dysfunction or mitochondrial failure. A broad anti-inflammatory like colchicine may be too non-specific to target these diverse mechanisms. Second, the timing of the intervention—starting weeks or months after the initial infection—might be too late to reverse established physiological changes.
It is also worth noting the demographic context. The trial was conducted in India during a period dominated by various SARS-CoV-2 variants. While this provides valuable data for that specific population, the generalizability to other regions with different vaccination rates and variant exposures remains a point of discussion. However, given the robustness of the null findings, it is unlikely that colchicine would perform significantly better in other cohorts.
Conclusion: Moving Beyond General Anti-inflammatories
The study by Bassi et al. provides high-quality evidence that colchicine should not be routinely used for the treatment of Long COVID. While the search for effective therapies continues, this trial serves as a reminder of the necessity of rigorous, placebo-controlled evidence before adopting new treatments for complex syndromes.
Future research should focus on identifying specific biomarkers that can phenotype Long COVID patients, allowing for more targeted therapeutic trials. Approaches targeting viral reservoirs (such as antivirals), specific autoimmune pathways, or mitochondrial support may yield more promising results than general anti-inflammatory strategies.
Funding and Trial Registration
This study was supported by various institutional grants and followed rigorous ethical and clinical guidelines.
Trial Registration: Clinical Trial Registry of India: CTRI/2021/11/038234.
References
1. Bassi A, Devasenapathy N, Thankachen SS, et al. Effectiveness of Colchicine for the Treatment of Long COVID: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(12):1462-1470. doi:10.1001/jamainternmed.2025.5408.
2. Tardif JC, Bouabdallaoui N, L’Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a randomised, double-blind, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924-932.
3. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.